Investors Menu

Jennifer Simpson, PhD

Jennifer Simpson,, , Board Member, Nominating and Corporate Governance Committee

Dr. Simpson has been President and CEO of Delcath and a member of the board since May 2015. She previously served as interim President and Chief Executive Officer, joining Delcath in 2012 as Executive Vice President, Global Marketing.

Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as Vice President, Global Marketing, Oncology Brand Lead, where she was responsible for product commercialization activities and launch preparation for one of their late stage assets. Prior to ImClone, Dr. Simpson was Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech focused on innovative solutions in immunology, oncology and nephrology.

Early in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.

Investor Contact

Communications, Inc.
Lisa M. Wilson,

For all other media inquiries, please contact us.